alexa The pathogenesis of idiopathic pulmonary fibrosis.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Obesity & Weight Loss Therapy

Author(s): Coward WR, Saini G, Jenkins G

Abstract Share this page

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an appalling prognosis. The failure of anti-inflammatory therapies coupled with the observation that deranged epithelium overlies proliferative myofibroblasts to form the fibroblastic focus has lead to the emerging concept that IPF is a disease of deregulated epithelial-mesenchymal crosstalk. IPF is triggered by an as yet unidentified alveolar injury that leads to activation of transforming growth factor-β (TGF-β) and alveolar basement membrane disruption. In the presence of persisting injurious pathways, or disrupted repair pathways, activated TGF-β can lead to enhanced epithelial apoptosis and epithelial-to-mesenchymal transition (EMT) as well as fibroblast, and fibrocyte, transformation into myofibroblasts which are resistant to apoptosis. The resulting deposition of excess disrupted matrix by these myofibroblasts leads to the development of IPF. This article was published in Ther Adv Respir Dis and referenced in Journal of Obesity & Weight Loss Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 13th World Congress on Obesity
    Aug 24-25, 2017, Toronto, Canada
  • 13th Euro Obesity and Endocrinology Congress
    Sep 21-23, 2017, Madrid, Spain

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version